A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
NCT02081690
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
160
Enrollment
INDUSTRY
Sponsor class
Stopped
Slow recruitment
Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG:
Macitentan
Sponsor
Actelion